3Chensue SW, Ruth .JH, Wanning:on K, etal. In vivo regtdation of maerophage IL- 12 production during typel and type2 cytokine mediated granuloma for mation.Immunol 1995,155 : 3546 - 3551.
4Schranz D, Zartner P, Michel Behnke I, et al. Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newbom. Catheter Card iovasc Intew,2006,67(5) :671-673.
5Ovaert C, Benson LN, Nykanen D, et al. Transcatheter treament of coarctation of the aorta a review. Pechatr Cardiol, 1998,19( 1 ) :27-44.
6Cui, Sharmin, OkumuraY, et al. Endothelin - lpeptidesand IL - 5 synergistically increase the expression of IL - 13 ineosinophils. Biochem Biophys Res Commun,2004,315(4) :782-787.
7Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL- 13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. Allergy, Clin Immunol, 1997,99(5):657.
9Naseer T, Minshall EM, Letmg DY, et al. Expression of IL -12 and IL - 13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Meal,, 1997,155:845-851.
6Montuschi P, Barnes PJ. Exhaled leukotrienes and pro-staglandins in asthma. J Allergy Clin Immunol, 2002; 109(4) :615-620.
7National institutes of health, National heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Revised ,2006. http ://www. ginasthma. com/Guidelineitem. asp.
8Mitsunobu F, Mifune T, Hosaki Y, et al. Enhanced peripheral leukocyte leukotriene production and bronchial hyperesponsiveness in asthmatics. Eur Resp ir J , 2000; 16 (3) :504-508.
9Graeme PC, Daniel KC, Kay h, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid- treated patients with asthma. Am J Respir Crit Care Med, 2003, 16 (7): 1232-1238.
10Nakajima H, Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol,2007,142 (4) :265 -273.
